Carta científico-clínica
Ustekinumab en hidradenitis supurativa: a propósito de un caso
Ustekinumab for Hidradenitis Suppurativa: A Case Report
Leído
10303
Vecesse ha leído el artículo
2577
Total PDF
7726
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 34 | 6 | 40 |
| 2025 5 | 130 | 41 | 171 |
| 2025 4 | 125 | 25 | 150 |
| 2025 3 | 140 | 21 | 161 |
| 2025 2 | 128 | 31 | 159 |
| 2025 1 | 110 | 37 | 147 |
| 2024 12 | 106 | 29 | 135 |
| 2024 11 | 85 | 61 | 146 |
| 2024 10 | 70 | 47 | 117 |
| 2024 9 | 60 | 29 | 89 |
| 2024 8 | 79 | 40 | 119 |
| 2024 7 | 81 | 41 | 122 |
| 2024 6 | 123 | 28 | 151 |
| 2024 5 | 75 | 32 | 107 |
| 2024 4 | 71 | 20 | 91 |
| 2024 3 | 94 | 27 | 121 |
| 2024 2 | 95 | 34 | 129 |
| 2024 1 | 67 | 20 | 87 |
| 2023 12 | 173 | 19 | 192 |
| 2023 11 | 138 | 44 | 182 |
| 2023 10 | 85 | 29 | 114 |
| 2023 9 | 79 | 28 | 107 |
| 2023 8 | 76 | 16 | 92 |
| 2023 7 | 109 | 35 | 144 |
| 2023 6 | 90 | 17 | 107 |
| 2023 5 | 130 | 22 | 152 |
| 2023 4 | 144 | 19 | 163 |
| 2023 3 | 159 | 21 | 180 |
| 2023 2 | 118 | 24 | 142 |
| 2022 1 | 120 | 30 | 150 |
| 2022 12 | 125 | 36 | 161 |
| 2022 11 | 119 | 25 | 144 |
| 2022 10 | 136 | 38 | 174 |
| 2022 9 | 150 | 68 | 218 |
| 2022 8 | 99 | 35 | 134 |
| 2022 7 | 112 | 49 | 161 |
| 2022 6 | 122 | 31 | 153 |
| 2022 5 | 145 | 45 | 190 |
| 2022 4 | 97 | 37 | 134 |
| 2022 3 | 97 | 46 | 143 |
| 2022 2 | 87 | 36 | 123 |
| 2021 1 | 120 | 53 | 173 |
| 2021 12 | 77 | 34 | 111 |
| 2021 11 | 75 | 34 | 109 |
| 2021 10 | 87 | 41 | 128 |
| 2021 9 | 94 | 45 | 139 |
| 2021 8 | 76 | 25 | 101 |
| 2021 7 | 78 | 35 | 113 |
| 2021 6 | 97 | 45 | 142 |
| 2021 5 | 72 | 27 | 99 |
| 2021 4 | 315 | 51 | 366 |
| 2021 3 | 162 | 41 | 203 |
| 2021 2 | 104 | 31 | 135 |
| 2020 1 | 97 | 18 | 115 |
| 2020 12 | 81 | 13 | 94 |
| 2020 11 | 61 | 20 | 81 |
| 2020 10 | 67 | 17 | 84 |
| 2020 9 | 39 | 7 | 46 |
| 2020 8 | 52 | 23 | 75 |
| 2020 7 | 54 | 14 | 68 |
| 2020 6 | 47 | 16 | 63 |
| 2020 5 | 52 | 40 | 92 |
| 2020 4 | 45 | 18 | 63 |
| 2020 3 | 68 | 32 | 100 |
| 2020 2 | 8 | 14 | 22 |
| 2020 1 | 2 | 16 | 18 |
| 2019 12 | 4 | 4 | 8 |
| 2019 11 | 0 | 3 | 3 |
| 2019 10 | 2 | 14 | 16 |
| 2019 9 | 19 | 16 | 35 |
| 2019 8 | 0 | 11 | 11 |
| 2019 7 | 26 | 11 | 37 |
| 2019 6 | 14 | 12 | 26 |
| 2019 5 | 7 | 24 | 31 |
| 2019 4 | 1 | 17 | 18 |
| 2019 3 | 14 | 11 | 25 |
| 2019 2 | 33 | 12 | 45 |
| 2019 1 | 4 | 3 | 7 |
| 2018 12 | 21 | 1 | 22 |
| 2018 11 | 0 | 1 | 1 |
| 2018 10 | 7 | 5 | 12 |
| 2018 9 | 4 | 5 | 9 |
| 2018 8 | 1 | 6 | 7 |
| 2018 7 | 0 | 13 | 13 |
| 2018 6 | 0 | 9 | 9 |
| 2018 5 | 1 | 8 | 9 |
| 2018 4 | 0 | 9 | 9 |
| 2018 3 | 0 | 4 | 4 |
| 2018 2 | 44 | 8 | 52 |
| 2018 1 | 41 | 12 | 53 |
| 2017 12 | 54 | 11 | 65 |
| 2017 11 | 54 | 15 | 69 |
| 2017 10 | 53 | 10 | 63 |
| 2017 9 | 34 | 6 | 40 |
| 2017 8 | 39 | 13 | 52 |
| 2017 7 | 32 | 23 | 55 |
| 2017 6 | 44 | 17 | 61 |
| 2017 5 | 35 | 9 | 44 |
| 2017 4 | 26 | 13 | 39 |
| 2017 3 | 29 | 10 | 39 |
| 2017 2 | 16 | 13 | 29 |
| 2016 1 | 26 | 6 | 32 |
| 2016 12 | 32 | 9 | 41 |
| 2016 11 | 35 | 14 | 49 |
| 2016 10 | 40 | 15 | 55 |
| 2016 9 | 55 | 14 | 69 |
| 2016 7 | 7 | 1 | 8 |
| 2016 6 | 15 | 3 | 18 |
| 2016 5 | 13 | 0 | 13 |
| 2016 4 | 10 | 2 | 12 |
| 2016 3 | 14 | 1 | 15 |
| 2016 2 | 12 | 2 | 14 |
| 2015 1 | 8 | 3 | 11 |
| 2015 12 | 20 | 3 | 23 |
| 2015 11 | 20 | 3 | 23 |
| 2015 10 | 3 | 1 | 4 |
| 2015 9 | 4 | 1 | 5 |
| 2015 8 | 9 | 1 | 10 |
| 2015 7 | 32 | 8 | 40 |
| 2015 6 | 37 | 5 | 42 |
| 2015 5 | 48 | 9 | 57 |
| 2015 4 | 30 | 4 | 34 |
| 2015 3 | 30 | 8 | 38 |
| 2015 2 | 24 | 15 | 39 |
| 2015 1 | 22 | 7 | 29 |
| 2014 12 | 20 | 10 | 30 |
| 2014 11 | 19 | 10 | 29 |
| 2014 10 | 38 | 8 | 46 |
| 2014 9 | 31 | 26 | 57 |
Mostrar todo
